CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
-T treatment.This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against relapsed non- ...
Phase 1
Cleveland, Ohio, United States and 1 other location
ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a po-...
Phase 1
Cleveland, Ohio, United States and 13 other locations
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...
Phase 1
Cleveland, Ohio, United States and 27 other locations
in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL).Part 2: Cohort Expansion. The...
Phase 1, Phase 2
Cleveland, Ohio, United States and 25 other locations
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...
Phase 2
Cleveland, Ohio, United States and 55 other locations
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The ma...
Phase 1
Cleveland, Ohio, United States and 14 other locations
This study will enroll approximately 160 adult participants who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicab...
Phase 2
Cleveland, Ohio, United States and 18 other locations
This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL).T...
Phase 2
Cleveland, Ohio, United States and 137 other locations
if it works to treat the diseases under study. The diseases under study will be Renal Cell Carcinoma (RCC),Nasopharyngeal Carcinoma (NPC) and Non...
Phase 1, Phase 2
Cleveland, Ohio, United States and 17 other locations
This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in participants with CD20-positive lymphoprolifer...
Phase 1
Cleveland, Ohio, United States and 5 other locations
Clinical trials
Research sites
Resources
Legal